Effect of sorafenib (S) starting dose and dose intensity on survival in patients with hepatocellular carcinoma (HCC): Results from a Canadian multicenter HCC database.

Mohammed Abdullah Alghamdi,Richard M. Lee-Ying,Hao-Wen Sim,Haider Samawi,Jennifer J. Knox,Adriana Romagnino,Yoo Joung Ko,Kelvin K. Chan,Mina Swiha,Eugene Batuyong,Winson Y. Cheung,Vincent C. Tam

Effect of sorafenib (S) starting dose and dose intensity on survival in patients with hepatocellular carcinoma (HCC): Results from a Canadian multicenter HCC database.

2017

Mohammed Abdullah Alghamdi
Richard M. Lee-Ying
Hao-Wen Sim
Haider Samawi
Jennifer J. Knox
Adriana Romagnino
Yoo Joung Ko
Kelvin K. Chan
Mina Swiha
Eugene Batuyong
Winson Y. Cheung
Vincent C. Tam

4084Background: The SHARP trial showed that S improves survival in advanced HCC. Full dose (FD) S at 400mg bid can be difficult to tolerate, so some clinicians begin with a reduced dose (RD) & esca...

Keywords:

Pathology
Hepatocellular carcinoma
Cancer research
Sorafenib
Medicine
Oncology
in patient
reduced dose
dose intensity
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations